The purpose of this study was to evaluate differences between patients receiving 18F-fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. Methods: All 68Ga-PSMA-11 PET studies performed the University California San Francisco from October 2015 January 2...

Abstract Background Amino acid PET radiopharmaceutical, 18F-fluciclovine, shows increased uptake in brain tumors relative to normal tissue and may be a useful tool for detecting recurrent metastases. Here, we report results from prospective pilot study evaluating the use of 18F-fluciclovine PET/CT distinguish radiation necrosis tumour progression among patients with metastases treated stereotac...

objective(s): the study objective was to assess the diagnostic performance of positron emission tomography (pet) for gliomas using the novel tracer 18f-fluciclovine (anti-[18f]facbc) and to evaluate the safety of this tracer in patients with clinically suspected gliomas.methods: anti-[18f]facbc was administered to 40 patients with clinically suspected high- or low-grade gliomas, followed by pet...

You have accessJournal of UrologyProstate Cancer: Staging (MP11)1 Sep 2021MP11-15 REAL-WORLD EVIDENCE OF 18F-FLUCICLOVINE PET/CT UTILIZATION FOR RECURRENT PROSTATE CANCER IN THE VETERAN AFFAIRS HEALTH SYSTEM Zachary Klaassen, Lin Gu, Justin D. Waller, Amanda De Hoedt, Nancy Tainer, Jonathan Kinscherff, and Stephen J. Freedland KlaassenZachary Klaassen More articles by this author , GuLin Gu Wal...